Seroatlas · Human Serome Atlas

EBAG9

Receptor-binding cancer antigen expressed on SiSo cells

Also known as: EB9, RCAS1, RCAS1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O00559
Gene: EBAG9
Ensembl: ENSG00000147654
Chromosome: 8
Canonical length: 213 aa
Protein class: Cancer-related genes, Predicted intracellular proteins
Subcellular location: Golgi apparatus
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

213 residues, UniProt reviewed canonical sequence.

>O00559|EBAG9
     1  MAITQFRLFK FCTCLATVFS FLKRLICRSG RGRKLSGDQI TLPTTVDYSS VPKQTDVEEW
    61  TSWDEDAPTS VKIEGGNGNV ATQQNSLEQL EPDYFKDMTP TIRKTQKIVI KKREPLNFGI
   121  PDGSTGFSSR LAATQDLPFI HQSSELGDLD TWQENTNAWE EEEDAAWQAE EVLRQQKLAD
   181  REKRAAEQQR KKMEKEAQRL MKKEQNKIGV KLS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against EBAG9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Other membrane
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.64
Highest tissue expression: 50 nTPM

Expression across tissuesHPA

Tissue

thyroid gland: 50 nTPM
skeletal muscle: 44 nTPM
epididymis: 38 nTPM
salivary gland: 37 nTPM
tongue: 37 nTPM
liver: 36 nTPM

Single-cell type

late spermatids: 172 nCPM
late primary spermatocytes: 145 nCPM
early spermatids: 119 nCPM
epididymal principal cells: 106 nCPM
early primary spermatocytes: 93 nCPM
gastric chief cells: 93 nCPM

Immune cell

memory B-cell: 29 nTPM
naive B-cell: 29 nTPM
MAIT T-cell: 24 nTPM
naive CD4 T-cell: 23 nTPM
T-reg: 22 nTPM
NK-cell: 21 nTPM

Brain region

cerebellum: 29 nTPM
cerebral cortex: 25 nTPM
hypothalamus: 24 nTPM
basal ganglia: 23 nTPM
white matter: 22 nTPM
medulla oblongata: 22 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.73
gnomAD pLI: 0.08
gnomAD missense Z: 0.97
DepMap mean gene effect: -0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 17% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

peptidase activator activity involved in apoptotic process

Cellular components

Protein domainsUniProt · Pfam · InterPro

Cancer-associated antigen RCAS1

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads EBAG9 as an antibody target. Whether an autoantibody or antibody against EBAG9 could matter depends on whether native EBAG9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

EBAG9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label EBAG9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...